



CVE-2022-20813

[MITRE](#)[NVD](#)[CVE.ORG](#)[Print: PDF](#)

Summary

| | |
|------------------------|---|
| CVE | CVE-2022-20813 |
| State | PUBLIC |
| Assigner | psirt@cisco.com |
| Source Priority | CVE Program / NVD first with legacy fallback |
| Published | 2022-07-06 21:15:00 UTC |
| Updated | 2023-11-07 03:43:00 UTC |
| Description | Multiple vulnerabilities in the API and in the web-based management interface of Cisco Expressway Series and Cisco TelePresence Video Communication Server. |

Risk And Classification

Problem Types: CWE-295

NVD Known Affected Configurations (CPE 2.3)

| Type | Vendor | Product | Version | Update | Edition | Language |
|-------------|--------|---|---------|--------|---------|----------|
| Application | Cisco | Expressway | All | All | All | All |
| Application | Cisco | Telepresence Video Communication Server | All | All | All | All |

References

| Reference | Source | Link | Tags |
|--|---------|---|------|
| 20220706 Cisco Expressway Series and Cisco TelePresence Video Communication Server Vulnerabilities | CISCO | tools.cisco.com | |
| CVE Program record | CVE.ORG | www.cve.org | cc |
| NVD vulnerability detail | NVD | nvd.nist.gov | cc |

No vendor comments have been submitted for this CVE.

Legacy QID Mappings

[38875](#) Cisco Expressway Series and Cisco TelePresence Video Communication Server Vulnerabilities (cisco-sa-expressway-overwrite-3buqW8LH)

completeness or usefulness of any information, opinion, advice or other content. EACH USER WILL BE SOLELY RESPONSIBLE FOR ANY consequences of his or her direct or indirect use of this web site. ALL WARRANTIES OF ANY KIND ARE EXPRESSLY DISCLAIMED. This site will NOT BE LIABLE FOR ANY DIRECT, INDIRECT or any other kind of loss.

CVE, CWE, and OVAL are registered trademarks of [The MITRE Corporation](#) and the authoritative source of CVE content is [MITRE's CVE web site](#). This site includes MITRE data granted under the following [license](#).

CVE.report and Source URL Uptime Status [status.cve.report](#)